Abstract
The effective management of pharmaceuticals in the National Health Service (NHS) is critical to patient welfare thus any risks attached to this must be identified and controlled. At a very basic level, risks in the pharmaceutical supply chain are associated with product discontinuity, product shortages, poor performance, patient safety/dispensing errors, and technological errors (causing stock shortages in pharmacies) to name but a few, all of which incur risk through disruption to the system. Current indications suggest that the pharmaceutical industry and NHS practitioners alike have their concerns as to the use of generic supply chain strategies in association with what is perceived to be a specialist product (pharmaceuticals). The aim of the study undertaken was to gain a more realistic understanding of the nature and prevalence of risk in the Pharmaceutical Supply Chain (PSC) to be used as a basis for a more rigorous research project incorporating in-vestigation in the UK, Europe and USA. Data was collected via a workshop forum held in November 2005. The outputs of the workshop indicated that there were thirty-five prevalent risks. The risks were rated using risk assessment catego-ries such as impact, occurrence and controllability. The findings indicated that the risks identified are similar to those prevalent in industrial supply chains, regardless of the idiosyncrasies of pharmaceuticals. However, the group consen-sus was that caution must be applied in how such risks are addressed, as there are aspects of the product that highlight its uniqueness e.g. criticality.
Highlights
IntroductionAccording to Khan et al “Risk is an ever-present aspect of organisational life” [16] and “ there is a need to devise robust and well-grounded models of supply chain risk management, which incorporate risk management tools and techniques from other disciplines of research [16]”
According to Khan et al “Risk is an ever-present aspect of organisational life” [16] and “ there is a need to devise robust and well-grounded models of supply chain risk management, which incorporate risk management tools and techniques from other disciplines of research [16]”. Whilst this may be the case, there has been no research to date, which has investigated risks within the total Pharmaceutical Supply Chain (PSC) as pertinent to National Health Service (NHS) pharmacy
The authors above would support this sentiment arguing that risk management has only recently been seen as an issue that urgently needs to be addressed in supply chain management
Summary
According to Khan et al “Risk is an ever-present aspect of organisational life” [16] and “ there is a need to devise robust and well-grounded models of supply chain risk management, which incorporate risk management tools and techniques from other disciplines of research [16]” Whilst this may be the case, there has been no research to date, which has investigated risks within the total PSC as pertinent to NHS pharmacy. Academic researchers and practitioners believe that “pharmaceuticals are different; they cannot be treated like other commodities” [24] The reasons for this sentiment were the high cost and long duration for research and development and the repercussions of the product not being available, again its criticality. This may be an option for the PSC in the NHS (UK)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
